^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thymic Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Thymomas and Thymic Carcinomas: PRICIPLES OF SYSTEMIC THERAPY...Preferred…Pembrolizumab...